198 related articles for article (PubMed ID: 31121610)
21. Can metformin reduce insulin resistance in polycystic ovary syndrome?
Açbay O; Gündoğdu S
Fertil Steril; 1996 May; 65(5):946-9. PubMed ID: 8612854
[TBL] [Abstract][Full Text] [Related]
22. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables.
Holte J; Bergh T; Berne C; Lithell H
Clin Endocrinol (Oxf); 1994 Oct; 41(4):463-71. PubMed ID: 7955457
[TBL] [Abstract][Full Text] [Related]
23. Effect of metformin by employing 2-hour postload insulin for measuring insulin resistance in Taiwanese women with polycystic ovary syndrome.
Ou HT; Chen PC; Wu MH
J Formos Med Assoc; 2017 Feb; 116(2):80-89. PubMed ID: 27131512
[TBL] [Abstract][Full Text] [Related]
24. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
25. Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model.
Karateke A; Dokuyucu R; Dogan H; Ozgur T; Tas ZA; Tutuk O; Agturk G; Tumer C
Med Princ Pract; 2018; 27(6):515-522. PubMed ID: 30293079
[TBL] [Abstract][Full Text] [Related]
26. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
Singh S; Akhtar N; Ahmad J
Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
[TBL] [Abstract][Full Text] [Related]
27. Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy.
Diamanti-Kandarakis E; Economou FN; Livadas S; Tantalaki E; Piperi C; Papavassiliou AG; Panidis D
Kidney Blood Press Res; 2009; 32(1):24-31. PubMed ID: 19212122
[TBL] [Abstract][Full Text] [Related]
28. [Effects of metformin therapy on markers of coagulation disorders in hyperinsulinemic women with polycystic ovary syndrome].
Serdyńska-Szuster M; Banaszewska B; Spaczyński R; Pawelczyk L
Ginekol Pol; 2011 Apr; 82(4):259-64. PubMed ID: 21735693
[TBL] [Abstract][Full Text] [Related]
29. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance.
Tan S; Hahn S; Benson S; Dietz T; Lahner H; Moeller LC; Schmidt M; Elsenbruch S; Kimmig R; Mann K; Janssen OE
Eur J Endocrinol; 2007 Nov; 157(5):669-76. PubMed ID: 17984248
[TBL] [Abstract][Full Text] [Related]
30. Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy.
Berker B; Emral R; Demirel C; Corapcioglu D; Unlu C; Kose K
Gynecol Endocrinol; 2004 Sep; 19(3):125-33. PubMed ID: 15697073
[TBL] [Abstract][Full Text] [Related]
31. Several Circulating Biomarkers for PCOS Diagnosis.
Luo P; Zhang C; He Y; Yang G; Liu H; Li L
Exp Clin Endocrinol Diabetes; 2021 Oct; 129(10):705-712. PubMed ID: 31683329
[TBL] [Abstract][Full Text] [Related]
32. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome.
Berneis K; Rizzo M; Lazzarini V; Fruzzetti F; Carmina E
J Clin Endocrinol Metab; 2007 Jan; 92(1):186-9. PubMed ID: 17062762
[TBL] [Abstract][Full Text] [Related]
33. Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment.
Zheng S; Liu E; Zhang Y; Long T; Liu X; Gong Y; Mai T; Shen H; Chen H; Lin R; Zheng Y; Xie Y; Wang F
Endocr J; 2019 Jun; 66(6):555-562. PubMed ID: 30918134
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Effect of Curcumin in Women with Polycystic Ovary Syndrome Receiving Metformin: A Randomized Controlled Trial.
Sohrevardi SM; Heydari B; Azarpazhooh MR; Teymourzadeh M; Simental-Mendía LE; Atkin SL; Sahebkar A; Karimi-Zarchi M
Adv Exp Med Biol; 2021; 1308():109-117. PubMed ID: 33861440
[TBL] [Abstract][Full Text] [Related]
35. Assessment of PON1 activity and circulating TF levels in relation to BMI, testosterone, HOMA-IR, HDL-C, LDL-C, CHO, SOD activity and TAC in women with PCOS: An observational study.
Jeelani H; Ganie MA; Masood A; Amin S; Kawa IA; Fatima Q; Manzoor S; Parvez T; Naikoo NA; Rashid F
Diabetes Metab Syndr; 2019; 13(5):2907-2915. PubMed ID: 31425955
[TBL] [Abstract][Full Text] [Related]
36. [Advantages of Chinese medicine for treatment of blood sugar and lipid metabolic disorders in patients with polycystic ovarian syndrome].
Zhao H; Bao WF; Zhang T
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Jul; 29(7):595-8. PubMed ID: 19852289
[TBL] [Abstract][Full Text] [Related]
37. Treatment with Metformin and Combination of Metformin Plus Pioglitazone on Serum Levels of IL-6 and IL-8 in Polycystic Ovary Syndrome: A Randomized Clinical Trial.
Ali DE; Shah M; Ali A; Malik MO; Rehman F; Badshah H; Ehtesham E; Vitale SG
Horm Metab Res; 2019 Nov; 51(11):714-722. PubMed ID: 31683341
[TBL] [Abstract][Full Text] [Related]
38. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial.
Fux Otta C; Wior M; Iraci GS; Kaplan R; Torres D; Gaido MI; Wyse EP
Gynecol Endocrinol; 2010 Mar; 26(3):173-8. PubMed ID: 20148739
[TBL] [Abstract][Full Text] [Related]
39. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
Unlühizarci K; Keleştimur F; Bayram F; Sahin Y; Tutuş A
Clin Endocrinol (Oxf); 1999 Aug; 51(2):231-6. PubMed ID: 10468995
[TBL] [Abstract][Full Text] [Related]
40. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
